Phase 1/2 study of nab-paclitaxel in children with solid tumours

• Research type

  Research Study

• Full title

  A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab®-paclitaxel in pediatric patients with recurrent or refractory solid tumors.

• IRAS ID

  133720

• Contact name

  Andrew Pearson

• Contact email

  Andrew.Pearson@icr.ac.uk

• Sponsor organisation

  Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation

• Eudract number

  2013-000144-26

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  13/LO/1272

• Date of REC Opinion

  30 Oct 2013

• REC opinion

  Further Information Favourable Opinion